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Abstract: Methylene blue (MB) is used in human therapy in various pathological conditions. Its 
effects in neurodegenerative disease models are promising. MB acts on multiple cellular targets 
and mechanisms, but many of its potential beneficial effects are ascribed to be mitochondrial. Ac-
cording to the “alternative electron transport” hypothesis, MB is capable of donating electrons to 
cytochrome c bypassing complex I and III. As a consequence of this, the deleterious effects of the 
inhibitors of complex I and III can be ameliorated by MB. Recently, the beneficial effects of MB ex-
erted on complex III-inhibited mitochondria were debated. In the present contribution, several 
pieces of evidence are provided towards that MB is able to reduce cytochrome c and improve bio-
energetic parameters, like respiration and membrane potential, in mitochondria treated with com-
plex III inhibitors, either antimycin or myxothiazol. These conclusions were drawn from meas-
urements for mitochondrial oxygen consumption, membrane potential, NAD(P)H steady state, MB 
uptake and MB-cytochrome c oxidoreduction. In the presence of MB and complex III inhibitors, 
unusual respiratory reactions, like decreased oxygen consumption as a response to ADP addition 
as well as stimulation of respiration upon administration of inhibitors of ATP synthase or ANT, 
were observed. Qualitatively identical results were obtained in three rodent species. The actual 
metabolic status of mitochondria is well reflected in the distribution of MB amongst various com-
partments of this organelle. 
Keywords: oxidoreduction; NAD(P)H; cytochrome c; methylene blue; bioenergetics; compart-
ments; rodent mitochondria 
 
1. Introduction 
The synthetic drug methylene blue (MB) has been used in human therapy since the 
last decade of the nineteenth century [1]. Its indications are extended for a broad spec-
trum of diseases from the treatment of toxic conditions to even neurological diseases [2]. 
MB is useful in one way or another, e.g., to kill cells in the course of photodynamic 
therapy, or help cells survive. Currently, MB is used in medicine as a photosensitizer for 
antibacterial disinfection [3] and MB derivatives are promising as possible anticancer 
agents [4]. On the other hand, MB is an established antidote in cyanide poisoning [5] and 
approved for the treatment of methemoglobinemia [6] MB had promising effects on 
animal or in vitro models of neurodegeneration [7,8]. For recent reviews, see [9,10]. 
Complex III is at the crossroad of the respiratory complexes, accepting electrons 
from -glycerophosphate dehydrogenase, fatty acid oxidation, complex I and complex II 
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[11]. The electron transfer mechanism inside the complex has been a subject of dispute for 
a very long time. The complex consists of 11 protein components, 10 are encoded by the 
nuclear, while 1 by the mitochondrial DNA. Two sets of the 11 protein units [12] form the 
functional dimer complex [13]. Until 2015 ten mutations in different proteins were asso-
ciated with CIII deficiency [14]. True disease conditions are rarely associated with com-
plex III, although the diagnosis is not easy in the absence of specific symptoms. A recent 
summary of these diseases conditions is reviewed by [14]. Complex III is one of the major 
reactive oxygen species (ROS) forming sites in the mitochondria [15–17]. Inhibition of 
CIII by antimycin or myxothiazol results in a very high rate of ROS production [18,19]. 
These inhibitors act on different sites of CIII’s “Q cycle” [20].  
The mitochondrion is a target for MB: the mitochondrial connection has been ex-
plored in 255 recent scientific articles. The beneficial effects of MB exerted on respiratory 
chain-inhibited mitochondria are summarized in the “alternative electron transport” 
theory [21,22]. According to that, MB can accept electrons from NADH+H+ and/or from 
the FMN functional group of complex I and can reduce cytochrome c bypassing CI and 
CIII.  
Earlier, it was published by our group that MB can beneficially affect the bioener-
getic parameters of mitochondria after inhibiting complex I or complex III [23]. More re-
cently, partially contradictory results were also published by others [24]. According to 
their results, the inhibition of complex III by antimycin cannot be bypassed by methylene 
blue, because MB donates electrons proximal to the antimycin binding site of CIII in 
mice. The authors of the latter study argued that the contradiction between their results 
and ours is probably due to differences in the examined species. Surveying the literature, 
we were unable to find data that display crucial qualitative differences in the basic bio-
energetics of mitochondria isolated from the brain of various rodent species. However, 
the negative results always refer to a particular problem and the generalization can be 
misleading. 
The aim of this study was to reinvestigate whether inhibition of the mitochondrial 
respiratory complex III (at various sites) could perhaps be overcome or bypassed by MB. 
In order to assess potential species-specific characteristics, experiments were performed 
on three different rodent species (guinea pig, mouse and rat). It has also been investi-
gated in model systems and in mitochondria as well, whether MB could donate electrons 
directly to cytochrome c. Besides corroborating our earlier results, i.e., proving the bene-
ficial effects of MB on isolated brain mitochondria treated with CIII inhibitors; antimycin 
A or myxothiazol, unusual bioenergetic reactions to ADP and the adenine nucleotide 
translocase (ANT) inhibitor carboxy-atractylate (CAT) are described and analyzed in the 
presence of complex III inhibitors and MB. It is concluded that (i) MB can partially 
overcome the inhibition of CIII mediated by either antimycin or myxothiazol, (ii) MB can 
directly transfer electrons to cytochrome c, (iii) the unusual bioenergetic reactions in the 
presence of MB and CIII inhibitors namely an ADP-mediated inhibition of respiration, 
increase in NADH/NAD+ steady state, and the CAT-induced increase in oxygen con-
sumption rate (OCR) and decrease in the NADH/NAD+ ratio are also spe-
cies-independent and can potentially all be attributed to the oxidation-reduction de-
pendent shuttling of MB between the mitochondria and the extramitochondrial space. 
2. Materials and Methods  
2.1. Isolation of Brain Mitochondria 
Mitochondria of synaptic and nonsynaptic origin were isolated from three different 
rodent species (mouse, rat and guinea pig) brain. Animals were decapitated via a pro-
cedure that is in accord with the International Guiding Principles for Biomedical Re-
search Involving Animals and Guidelines for Animal Experiments at Semmelweis Uni-
versity. According to the EU Directive “ Directive 2010/63/eu of the European Parliament 
and of the Council of 22 September 2010 on the protection of animals used for scientific 
Antioxidants 2021, 10, x FOR PEER REVIEW 3 of 27 
 
purposes” (Chapter 1, Article 3, Definitions 1, Paragraph 2: “killing the animals solely for 
the use of their organs or tissues”), the applied procedure above does not require any 
further specific permission. A discontinuous Percoll gradient was used for isolation of 
mitochondria, as was detailed earlier [25,26]. At the end of the centrifugation steps, the 
pellet was resuspended in buffer B (in mM: 225 mannitol, 75 sucrose, 5 Hepes, pH 7.4 
(KOH)) to about 30 mg/mL mitochondrial protein concentration. Mitochondrial protein 
concentration was determined by the modified Biuret reaction [27]. Mitochondria were 
prepared and were used within 4 hours in each experiment. Unless otherwise indicated 
0.1 mg/mL mitochondrial protein concentration was applied for most experiments. 
2.2. Chemicals and Standard Assay Medium 
All laboratory chemicals, except for ADP, were purchased from Sigma (St. Louis, 
MO, USA). ADP was purchased from Merck (Darmstadt, Germany). Experiments were 
carried out in a standard assay medium containing (in mM): 125 KCl, 20 Hepes, 2 
K2HPO4, 1 MgCl2, 0.1 EGTA, pH 7.0 (KOH)), supplemented with 0.025% fatty-acid-free 
bovine serum albumin (BSA). 
2.3. Measurement of Mitochondrial Oxygen Consumption 
Mitochondrial oxygen consumption assays were performed using the 
high-resolution respirometry system Oxygraph-2K (Oroboros Instruments, Innsbruck, 
Austria) [28] at 37 °C in 2 mL chambers. Oxygen consumption rate was calculated as the 
negative time derivative of the oxygen concentration. Oxygen sensors were calibrated at 
air saturation and in oxygen-depleted medium. Mitochondria (0.1 mg/mL mitochondrial 
protein) were energized with pyruvate plus malate (5 mM each) or glutamate plus malate 
(5 mM each). 
2.4. Measurement of Mitochondrial Membrane Potential (Δψm) 
ΔΨm was determined with two different methods. The first uses the cationic dye 
safranin O, which is accumulated and quenched in energized mitochondria [29]. The dye 
concentration was 2 M. The excitation and emission wavelengths were 495 and 585 nm, 
respectively, as described previously [30]. Fluorescence was detected in a PTI Deltascan 
fluorescence spectrophotometer (Photon Technology International, Lawrenceville, NJ, 
USA). 
In certain experiments mitochondrial membrane potential (Δψm) was detected sim-
ultaneously with O2 consumption by Oroboros O2k equipped with the O2k-LED2 
Fluo-Module, excitation LED 465 nm short-pass filter and emission long pass filter using 
fluorescent dye safranin O (2 µM). This approach made it possible to have entirely iden-
tical conditions for the OCR and Δψm measurements. Measurements using the dedicated 
fluorescence spectrophotometer (PTI Deltascan, Lawrenceville, NJ, USA) and the Oro-
boros O2k-LED2 Fluo-Module gave identical results. 
The second method uses tetramethylrhodamine methyl ester (TMRM) in a rati-
ometric mode, which was described earlier [31,26]. Fluorescence was detected in the dual 
excitation ratiometric mode in a PTI Deltascan fluorescence spectrophotometer (Photon 
Technology International, Lawrenceville, NJ, USA) using excitation wavelengths of 546 
and 573 nm and emission wavelength of 590 nm. The ratio of the fluorescence emitted at 
590 nm using the two excitation wavelengths was plotted. 
2.5. NAD(P)H Fluorescence Assay 
NAD(P)H autofluorescence in the matrix was monitored using a PTI Deltascan flu-
orescence spectrophotometer, as was described earlier [30]. Mitochondria (0.1 mg/mL) 
were incubated at 37 °C in the standard medium (see above), while fluorescence was 
detected via 344 nm (excitation)/460 nm (emission) wavelengths. Alterations in the 
NAD(P)H level were expressed as photon counts * 103. 
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2.6. Measurement of Oxidoreduction State and Localization of MB 
Oxidoreduction state of MB was monitored by the absorbance changes at 660 nm. 
MB in its oxidized form displays an absorption maximum at 660 nm. Mitochondria (0.1 
mg/mL) were incubated at 37 °C in the standard medium (see above), while absorption of 
MB was detected at 660 nm. In order to take into account the MB-independent absorb-
ance changes at 660 nm, measurements were repeated in the absence of MB as well, and 
the corresponding traces were subtracted from the traces obtained in the presence of MB. 
In order to follow the localization (extramitochondrial or intramitochondrial) of MB, 
mitochondria (0.4 mg/mL) were incubated in the reaction medium at 1 min MB (2 M) 
was added followed by pyruvate plus malate (5-5 mM), then by uncoupler carbonyl cya-
nide-4-(trifluoromethoxy)phenylhydrazone (FCCP) (250 nM). Absorbance (660 nm) was 
detected (incubation with mitochondria). After the addition of MB, pyruvate plus malate 
and FCCP aliquots were taken from the incubations (aliquots 1, 2, and 3) centrifuged for 2 
min at 14,300* g and absorbance at 660 nm was measured (supernatant). Cuvettes con-
taining the supernatants were bubbled with oxygen to fully oxidize MB (oxygen treat-
ment), then treated with dithionite to fully reduce MB (dithionite). Absorbance at 660 nm 
was detected by a JASCO V-650 spectrophotometer (ABL&E-JASCO, Tokyo, Japan). 
2.7. Statistical Analysis 
Data are presented as the means ± S.E.M. Statistical differences were evaluated with 
ANOVA (SIGMASTAT; Systat Software Inc., San Jose, CA, USA) followed by the Bon-
ferroni’s post-hoc test for multiple comparisons, or for data not following normal dis-
tribution with ANOVA on ranks Kruskal–Wallis test was applied. Student’s t-tests were 
used for simple comparisons. Values of p < 0.05 were considered to be significant. 
3. Results 
Below, results that were obtained utilizing three different rodent species are pre-
sented. Where it could be justified, however, data from only a single species are reported 
(to limit the length of the article). In these cases, the results obtained using the other spe-
cies are available in the Supplementary Materials. The purpose of this apparently ran-
dom presentation is to illustrate that measurements performed on different rodent spe-
cies can be fitted into the same puzzle without changing the general conclusions of the 
paper. 
3.1. Effects of Methylene Blue (MB) on the Oxygen Consumption of Complex III-Inhibited 
(Antimycin or Myxothiazol) Mitochondria Supported by Two Substrates in Three Different 
Species 
Oxygen consumption is a sensitive parameter of mitochondrial bioenergetics. Oxy-
gen consumption was measured in three rodent species (rat, mouse and guinea pig) ap-
plying either of two complex III inhibitors (antimycin or myxothiazol) and two respira-
tory substrates (pyruvate plus malate (PM) or glutamate plus malate (GM)) in combina-
tion and with ADP, the adenine nucleotide translocase (ANT) inhibitor carboxy-
atractylate (CAT) or ATP synthase inhibitor oligomycin (oligo) as well as the uncoupler 
FCCP. 
In agreement with the conclusions drawn from our earlier report on guinea pig mi-
tochondria [23], the oxygen consumption rate (OCR) was inhibited again by antimycin in 
mouse brain mitochondria supported by PM. Addition of MB (2 M) to antimy-
cin-treated mitochondria stimulated the oxygen consumption by 60% (from 36.7 ± 2.0 to 
58.7 ± 2.3 nmol/min/mg protein Figure 1D). The addition of ADP, however, did not sig-
nificantly alter the OCR of antimycin treated mitochondria, whereas it unexpectedly de-
creased the rate of oxidation (from 58.7 ± 2.3 to 36.4 ± 2.6 nmol/min/mg protein) in mito-
chondria treated with antimycin and MB. Inhibition of the ANT by CAT significantly 
stimulated the rate of respiration (by 51% from 36.4 ± 2.6 to 55.1 ± 2.4 nmol/min/mg pro-
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tein) in mitochondria treated with antimycin-MB-ADP. Stimulation of respiration by the 
ANT inhibitor was an unusual phenomenon. The addition of the uncoupler FCCP had an 
inhibitory effect on oxygen consumption. In the absence of MB, the antimycin-inhibited 
respiration was unaffected by either ADP or CAT. 
Considering that antimycin in the applied concentration did not completely inhibit 
the mitochondrial oxidation, the effects of another well-known inhibitor of complex III 
were also studied. The sites of inhibition within complex III are different for the two in-
hibitors [20]. Myxothiazol exerted a more pronounced effect on the PM-supported oxy-
gen consumption; the degree of inhibition was 88% (from 36.7 ± 2.0 to 4.5 ± 0.6 
nmol/min/mg Figure 1C). MB (2 M), however, increased the rate of oxidation by a factor 
of five (from 4.5 ± 0.6 to 22.7 ± 4.3 nmol/min/mg). Similar to that observed in antimycin 
plus MB treated mitochondria, added ADP decelerated the oxygen consumption whereas 
CAT stimulated it (Figure 1C). Representative traces are shown in Figure 1A, B. 
 
Antioxidants 2021, 10, x FOR PEER REVIEW 6 of 27 
 
 
Antioxidants 2021, 10, x FOR PEER REVIEW 7 of 27 
 
Figure 1. Effects of methylene blue (MB) (2 M) on the rate of oxygen consumption in complex III-inhibited mouse mi-
tochondria. In pyruvate plus malate (5-5 mM) supported mitochondria myxothiazol (1 M) (A,C) or antimycin A (0.3 M) 
(B,D) was applied for inhibiting of complex III. In (E), in the absence of inhibitors, buffer or MB was added. Representa-
tive original traces are shown in panels A and B. For traces denoted with black line inhibitor was only added, for traces 
represented with dotted lines, inhibitor and MB were both added. Further additions were as indicated. In (C,D,E), bars 
represent the average rates of oxygen consumption in nmol/min/mg protein ± S.E.M. (n = 8). * and # designate significant 
difference (p < 0.05) relative to the conditions indicated. 
Consistent results could be obtained from experiments, conducted under identical 
conditions, addressing the oxygen consumptions of guinea pig or rat brain mitochondria. 
Bar charts of the summarized results are shown for guinea pig (Figure S1) and rat (Figure 
S2) mitochondria in the supplementary material. Exchanging the pyruvate plus malate 
substrate combination to glutamate plus malate support, the latter did not affect the 
fundamental findings: inhibition of complex III by either myxothiazol or antimycin 
hampered the oxidation of complex I substrates, while MB could relieve this effect; in 
most cases, with MB the rate of oxidation was higher than the basal respiration detected 
in the absence of complex III inhibitors (myxothiazol or antimycin) in sub-
strate-supported mitochondria. 
The unusual pattern of oxidation detected in the presence of MB and either myxo-
thiazol or antimycin made us initiate studies for detecting potential changes in Δψm in 
order to clarify the mechanism behind the ADP-induced decrease and CAT-evoked 
stimulation of oxygen consumption. 
3.2. Membrane Potential (ΔΨm) in Complex III-Inhibited (Myxothiazol or Antimycin) 
Mitochondria is Partially Restored by MB in Mice and Rats 
Δψm was semiquantitatively measured using two fluorescent methods. Using safra-
nin fluorescence is simple and the measurement provides; reliable results. Safranin flu-
orescence is decreased with the hyperpolarization of Δψm. TMRM fluorescence was also 
measured in order to avoid various possible optical artifacts. The dual excitation rati-
ometric mode of the TMRM fluorescence measurements gives mirror images using the 
two excitation wavelengths [31]. TMRM fluorescence ratio is increased with the hy-
perpolarization of Δψm. 
3.2.1. Measurement of Δψm Using the Fluorescent Dye Safranin O 
The experimental protocol for the determination of Δψm by safranin was identical to 
that of the oxygen consumption measurements. In fact, in many cases, these two param-
eters were measured using the same cuvette equipped with an oxygen electrode and 
fluorescence light source/sensor unit. Complex III inhibitors almost completely depolar-
ized the mitochondria that were supported by NADH-generating substrates. ADP did 
not alter the low Δψm in electron transport chain (ETC) impaired mitochondria. The ANT 
inhibitor CAT only induced moderate repolarization, which was afterward abolished 
again by the uncoupler FCCP. In complex III-inhibited mitochondria, MB that was added 
after the inhibitors induced significant repolarization (Figure 2). The addition of ADP 
induced depolarization (like in non-inhibited mitochondria), and this depolarization was 
followed by a polarization event evoked by the ANT inhibitor CAT. Eventually, the un-
coupler FCCP completely dissipated Δψm. The difference in fluorescence induced by MB 
proved to be statistically significant in inhibitor-treated mitochondria. Similarly, the 
ADP-induced depolarization and CAT-evoked polarizations were also statistically sig-
nificant. Experiments utilizing rats (Figure S3) and either of the two inhibitors provided 
similar results. To verify the results obtained with safranin O and exclude potential op-
tical artifacts, experiments were also performed utilizing another fluorescent dye 
(TMRM). 
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Figure 2. Effects of MB (2 M) on the membrane potential in complex III-inhibited mouse mito-
chondria. Δψm was measured via safranin O fluorescence as described in Materials and Methods. 
Safranin was applied to pyruvate plus malate (5-5 mM) supported mitochondria; myxothiazol (1 
M) was used for inhibiting complex III. Trace a, red: inhibitor (myxothiazol) was added, trace b, 
blue: inhibitor and MB were added, trace c, green: MB was added, and trace d, pink: control con-
dition. Further additions were: ADP (2 mM), CAT (2 M), FCCP (250 nM), all as indicated. Traces 
represent the average safranin signals ± S.E.M at n = 3. *, #, &, $ represent significant difference (p < 
0.05) relative to the conditions indicated. 
3.2.2. Determination of Δψm via TMRM Fluorescence 
TMRM (in ratiometric mode) and safranin provided essentially identical results in 
fluorescence measurements (Figure 3). Experiments utilizing rats (Figure S4) or mice 
(Figure S5) and either of the two inhibitors provided similar results. 
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Figure 3. Effects of MB on the membrane potential (Δψm) of the complex III-inhibited (A): myxothiazol, (B): antimycin 
treated guinea pig mitochondria. Δψm was measured by tetramethylrhodamine methyl ester (TMRM) fluorescence as 
was described in Materials and Methods. The standard medium (see Materials and Methods) with TMRM (100 nM) was 
applied to the pyruvate plus malate (5-5 mM) supported mitochondria. Trace a, red: myxothiazol (myxo, 1 M) or anti-
mycin (anti, 0.3 M) was added, trace b, blue: inhibitors and MB (2 M) were added, trace c, green: MB was added, trace 
d, pink: buffer was only added. Further additions were as follows: ADP (2 mM), CAT (2 M), and FCCP (250 nM), all as 
indicated. Traces are representatives of three independent measurements. 
3.3. Measurement of the NAD(P)H Steady State 
Alterations in the NAD(P)H/NAD(P)+ steady state can provide a reliable assessment 
of the redox homeostasis of mitochondria. Inhibition of Complex I, III, and IV may affect 
the NAD(P)H homeostasis. Proximal to the block the oxido-reduction steady states of the 
reducing equivalents NADH/NAD+ and FADH2/FAD are expected to be shifted towards 
the respective more reduced forms [32]. The above-mentioned reducing equivalents are 
predominant electron donors for MB [21,23]. If MB were able to bridge the complex III 
inhibitors mediated reduction of the electron transport chain, this should also be reflected 
in somewhat attenuated NAD(P)H signals. Therefore, in complex III inhibited mito-
chondria, a certain degree of oxidation of NAD(P)H was indeed expected. Antimycin has 
its own optical signal at the wavelengths used in these experiments, therefore only the 
results obtained with myxothiazol-inhibited mitochondria are presented here (Figure 4). 
In the presence of respiratory substrates pyruvate plus malate the NAD(P)+ pool became 
promptly reduced. In the absence of myxothiazol (trace a, blue line), MB and the subse-
quently administered ADP both induced a marked degree of oxidation of NAD(P)H, 
while inhibition of the ANT by CAT reduced the pyrimidin nucleotide pool back again. 
Analogous results were obtained in the absence of MB (trace d, pink line). In the absence 
of MB, myxothiazol further increased the NAD(P)H level, however, the complex 
III-inhibited mitochondria did not react to ADP and CAT, the NAD(P)H level remained 
steady, and only FCCP induced a slow decrease in the NAD(P)H fluorescence (trace b, 
green line). In mitochondria treated with both myxothiazol and MB (trace c, red line), 
after the myxothiazol-evoked increase of NAD(P)H steady state addition of MB resulted 
in a drop of NAD(P)H level. The addition of ADP contrary to that shown in trace a in-
creased the NAD(P)H fluorescence, however, CAT oxidized the part of NAD(P)H pool. It 
is concluded that both myxothiazol and MB has an effect on the NAD(P)H level and the 
two compound applied in the same experimental results unexpected effects on the 
NAD(P)H redox equilibrium. Experiments performed with either guinea pigs (Figure S6) 
or mice (Figure S7) provided similar results. 




Figure 4. The effects of MB (2 M) on NAD(P)H steady state of complex III-inhibited rat mito-
chondria. In pyruvate plus malate-supported ((PM) 5-5 mM) mitochondria myxothiazol ((myxo) 1 
M) was employed for inhibiting complex III. Trace a, blue: MB was added; trace b, green: inhibitor 
(myxo) was added; trace c, red: myxo and MB were added, trace d, pink: solvent and buffer were 
added. Further additions were as indicated. Traces are representatives of at least three independent 
experiments and are offset for clarity. 
3.4. Oxido-Reduction of MB in the Presence or Absence of Inhibitors 
The observed changes in oxygen consumption, membrane potential and NAD(P)H 
level as a consequence of administering complex III inhibitors and MB appeared to con-
tradict one another. Usually, ADP depolarizes the Δψm and decreases the NAD(P)H level. 
Moreover, the inhibition of ANT generally decelerates the oxygen consumption while 
hyperpolarizing the mitochondria and increasing the NAD(P)H concentration. However, 
under the conditions applied in our experiments, we observed unexpected responses. In 
order to resolve these contradictions, we also attempted to determine the oxidoreduction 
state of MB on the basis of the distinct spectral signatures of its oxidized and reduced 
forms. MB in its oxidized form displays the maximum absorbance at 660 nm. Experi-
ments for Figure 5. utilized the following protocol (similarly to Figs. 1–4.): mitochondria, 
substrate, inhibitor, MB, ADP, CAT, FCCP. Experiments were terminated by adding di-
thionite; this compound reduced and hence discolored MB. 
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Figure 5. The effects of complex III-inhibitors on oxidoreduction steady state of MB (2 M) in mouse mitochondria. Ex-
periments were performed as described in Materials and Methods. In pyruvate plus malate-supported (5-5 mM) mito-
chondria absorbance differences (Abs660 * 103) were detected in the presence or absence of MB in (A): uninhibited (B): 
myxothiazol (C): antimycin treated mitochondria. Further additions were as indicated. Curves represent the average of 
three independent experiments ± S.E.M. 
In order to take into account the changes of absorbance at 660 nm in the absence of 
MB, traces obtained in the absence of MB at 660 nm were subtracted from the traces ob-
tained in the presence of MB. Summary curves depicted in Figure 5. demonstrate that the 
addition of MB in either the presence or absence of complex III inhibitors resulted in a 
large increase in the absorbance at 660 nm, which wavelength is attributed to the oxi-
dized form of MB. ADP evoked the oxidation of MB, inhibition of the ANT partially 
re-established the previous steady state, in the presence of FCCP MB became more oxi-
dized, and sodium dithionite reduced and discolored the MB pool. Analogous results 
were obtained with mitochondria isolated from the guinea pig brain as well (Figure S8). 
Traces without subtraction of MB-free absorbance are presented in Figure S9. 
3.5. Changes in Mitochondrial Bioenergetics May Modify the Compartmentalization of MB 
It is very likely that MB given to isolated mitochondria is not localized entirely 
within the mitochondrial compartments. It is known that the oxidized MB, which pos-
sesses an overall positive charge, can be taken up by mitochondria [33]. Oxidized MB has 
an absorption maximum of 660 nm. Experiments were performed to describe the distri-
bution and oxidoreduction state of MB added to non-energized, respiratory sub-
strate-supported and uncoupled mitochondria isolated from guinea pig brain (Figure 6). 
 
 
Figure 6. Distribution of MB among mitochondrial and non-mitochondrial compartments in various energetic conditions 
of the organelle. Guinea pig mitochondria were incubated in the standard assay medium as was described in the Mate-
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rials and Methods. Additions were as follows MB (2 M) at 1 min; PM 5-5 mM at 3 min and FCCP 250 nM at 5 min, and 
the absorbances at 660 nm were measured. Two minutes after each addition, aliquots were collected, mitochondria were 
sedimented and the absorbance of the supernatant was determined. Then, O2 gas was bubbled through all of the super-
natant samples for 2 min, and a subsequent reduction step was also carried out by using excess sodium dithionite. Ab-
sorbances were also recorded after performing the O2 and dithionite treatments. Curves represent the average of ten in-
dependent experiments ± S.E.M. *, # represent significant differences (p < 0.05) relative to the conditions indicated. 
The addition of MB (2 M) to substrate-free mitochondria leveled up the absorbance 
of the solution at 660 nm. Energization of mitochondria with the respiratory substrate 
pyruvate plus malate decreased the absorbance indicating the reduction of MB. The un-
coupling of the mitochondria with FCCP shifted the [oxidized]/[reduced] ratio of MB 
towards the more oxidized state (Figure 6a). Aliquots were collected and sedimented 
from the mitochondrial incubations and the absorbance of the mitochondrion-free su-
pernatants was determined (Figure 6b). The lowest absorbance was measured in the su-
pernatants of energized mitochondria. An equally high level of MB could be detected in 
the supernatants of the substrate-free and uncoupled mitochondria. In order to oxidize 
the MB of the supernatants completely, gas oxygen was bubbled through the cuvettes. 
There was no significant change detected between the non-oxygenated and the oxy-
gen-saturated samples indicating that the majority of MB in the supernatant was in the 
oxidized form. Reducing agent sodium dithionite was applied to the same samples and a 
significant decrease of 660 nm absorbance was detected, indicating that the colored sub-
stance was indeed the MB (Figure 6d). Results depicted in Figure 6. indicate that MB is 
taken up into energized mitochondria and will be reduced there. Deenergetization of 
mitochondria by uncoupler FCCP results in an almost complete release of MB decisively 
in the oxidized form. 
The aim of the following experiments was to give support to the hypothesis that MB 
could stimulate the transfer of electrons from NADH to cytochrome c (cyt. c). 
3.6. Reducing Equivalent NADH Can Reduce Cytochrome c in the Presence of MB 
3.6.1. Cytochrome c Reduction is also Stimulated by MB in the Presence of Complex III 
Inhibitors as Well 
Mitochondria isolated from guinea pig brain were supported by pyruvate plus mal-
ate. Exogenous acetyl-cytochrome c (ac-cyt. c) was present in the reaction medium from 
the beginning of the experiments. In the absence of MB and in either the presence or ab-
sence of CIII inhibitors, reduction of ac-cyt. c could not be observed (Figure 7A, B curves 
(a) and (d)). However, in the presence of MB, the energized mitochondria were able to 
reduce cyt. c, even in the presence of CIII inhibitors (Figure 7). The rate of reduction, 
however, was different in the presence (trace b, blue) and absence (trace a, green) of the 
inhibitors. In the absence of the inhibitors, the addition of MB provoked a higher rate of 
cyt. c reduction. ADP lowered the rate of cyt. c reduction in both the absence and pres-
ence of the inhibitors. The ATPase inhibitor oligomycin stimulated the cyt. c reduction, 
while depolarization of the inner mitochondrial membrane reversed that. This experi-
ment proved that exogenous ac-cyt. c can be reduced by MB. 
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Figure 7. Effects of MB on the reduction of exogenous ac-cyt. c in the complex III-inhibited (A): 
myxothiazol, (B): antimycin treated guinea pig mitochondria. Reduction of exogenous ac-cyt. c 
was measured at 550 nm wavelength. The standard medium (see Materials and Methods) was 
supplemented with ac-cyt. c (25 M). Guinea pig brain mitochondria were supported by pyruvate 
plus malate (5-5 mM). Trace a, red: myxothiazol (myxo, 1 M) or antimycin (anti, 0.3 M) was 
added, trace b, blue: inhibitors and MB (0.5 M) were added, trace c, green: MB was added, trace d, 
pink: buffer was only added. Further additions were as follows: ADP (2 mM), CAT (2 M), and 
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FCCP (250 nM), all as indicated. Numbers above the curves indicate the rate of absorbance chang-
esA550/sec * 10-6. Straight lines were fitted to various parts of the curves and slopes were calcu-
lated. Traces are averages of three independent measurements ± S.E.M. 
3.6.2. In the Presence of NADH MB is able to Reduce Cytochrome c in vitro 
A question to be answered was whether the reduced MB is able to reduce cyt. c. In 
order to elucidate this, an NADH solution in the standard medium was examined with a 
high-resolution oxygen electrode to determine the actual oxygen concentration. The ox-
ygen consumption of this solution was moderate. Upon administering MB, the oxygen 
consumption rate was immediately increased. The rate of oxygen consumption was 
gradually decreased as NADH was oxidized by MB (Figure 8). When ac-cyt. c was add-
ed, the oxygen consumption rate was immediately dropped then started to increase more 
slowly than in the absence of cyt. c. When reaching a plateau (attributed to the 
near-complete reduction of ac-cyt. c), the slopes of the two curves (traces c and d) became 
equal. This experiment indicated that MB was able to accept electrons from NADH and 
in the absence cyt. c it reacted with molecular oxygen. This is reflected in the enhanced 
oxygen consumption in the presence of NADH and MB. Ac-cyt. c, which is less prone to 
autoxidation, could react with MB, and this reaction decelerated the autoxidation of MB 
by O2. As ac-cyt c became more and more reduced, it eventually stopped accepting elec-
trons and the two rates became equal (traces c and d). The results presented above, 
however, provided indirect proof for the participation of cyt. c in the oxidation of NADH. 
 
 
Figure 8. Effects of MB and ac-cyt. c on the oxygen consumption in the presence of NADH. The 
standard medium (see Materials and Methods) was supplemented with NADH (250 M). All of the 
traces were supported by MB (2 mM) and ac-cyt. c (trace a, blue 25 M; trace b, red 12.5 M, trace c, 
green 5 M, trace d, pink 2 M). Traces are representatives of three independent measurements. 
3.6.3. NADH-Dependent Reduction of Acetylated Cytochrome c in the Presence of MB 
In order to detect directly the electron transfer between MB and cyt. c, the reduction 
of cyt. c by MB was measured (Figure 9). In the absence of NADH no substantial reduc-
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tion of ac-cyt. c could be observed (Figure 9. trace a, blue). However, the addition of MB 
(2 M), evoked a high rate of ac-cyt. c reduction, the rate was dependent upon the NADH 
concentration. 
 
Figure 9. Effects of MB on the reduction of ac-cyt. c in the presence of NADH in various concen-
trations. Reduction of ac-cyt. c was measured at 550 nm wavelength. The standard medium (see 
Materials and Methods) was supplemented with ac-cyt. c (25 M) and NADH (trace a, blue 0 M; 
trace b, red 50 M; trace c, green 250 M; trace d, pink 500 M). The numbers above the traces in-
dicate the rate of ac-cyt c reduction (A550/sec * 10-6). Traces are representatives of three independ-
ent measurements. 
4. Discussion 
4.1. Can MB Relieve the Inhibition of Complex III? 
MB induced a significant increase in oxygen consumption in mitochondria treated 
with either antimycin or myxothiazol. These results are in good agreement with our 
previous findings, while they are quite inconsistent with those reported recently by an-
other group [24]. In the present study, mitochondria isolated from three different animal 
species were investigated and the drawn conclusions were nearly identical in all three 
systems. MB was able to stimulate the oxygen consumption in mitochondria treated with 
either antimycin or myxothiazol. In agreement with this, MB was also able to partially 
restore the Δψm, which was depolarized earlier by either inhibitor of complex III. In order 
to eliminate as much as possible the potential optical artifacts, two fluorescent dyes were 
utilized for detecting alterations in Δψm. The two applied dyes both produced concordant 
results in all the three investigated species (safranin: Figure 2. mouse; Figure S3. rat, 
TMRM: Figure 3. guinea pig, Figure S4. rat, Figure S5. mouse). The validity of the results 
was further corroborated by the subsequent additions of ADP and the ANT inhibitor 
CAT. The addition of ADP to the inhibitor-treated but MB-rescued mitochondria depo-
larized the mitochondrial membrane, while the subsequent addition of CAT triggered 
polarization. The partial rescue of oxygen consumption as well as Δψm indicated that MB 
could indeed be beneficial under those pathological conditions that affect complex III. 
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4.2. Which Particular Segment of the Respiratory Chain Could Oxidize MB? 
Results depicted in Figure 1. (and Figs. S1 and S2) indicated that MB was able to re-
store the respiratory activities that were previously impaired by CIII inhibitors. Howev-
er, during this process, mitochondria were unable to completely reclaim the Δψm that 
could be detected in the absence of an inhibitor. These results can potentially be ac-
counted for by several mechanisms: i) since MB is also a well-known photosensitizer and 
hence ROS producer [24,34,3], it is possible that ROS formation by MB could be respon-
sible for the MB-induced oxygen consumption. However, the H2O2 formation detected in 
the presence of MB was more than one order of magnitude slower than the augmentation 
in the respective oxygen consumption (Figure 1.) calculated from [23]. The MB-induced 
bypassing of the inhibited complex III would lower the efficacy of the electron transfer 
system, from the 10H+/2e- to 2H+/2e-. This attenuation in the efficacy of proton gradient 
formation could permit a higher rate of electron transport with less Δψm built up. Indeed, 
in mitochondria inhibited by antimycin, MB could induce faster oxygen consumption 
than the inhibitor-free state. Although the membrane potential was not entirely 
re-established, a significant increase could still be detected. This and the simultaneously 
enhanced oxygen consumption indicated that the highly reduced electron transfer sys-
tem behind the block in the presence of MB could transfer electrons to electron acceptors 
shunting the block and the restarted electron transfer was associated with a higher rate of 
proton extrusion, i.e., with the partial repolarization of Δψm.  
According to Gureev et al. [24], the reduced form of MB could potentially donate 
electrons to complex III at the Qo site and that would be the reason why inhibition of CIII 
by antimycin (acting at the internal Qi site) could not be bypassed by MB. However, in 
the present study, when applying either the Qo site inhibitor myxothiazol or the Qi in-
hibitor antimycin, MB proved to be equally effective. Nevertheless, our data do not ex-
clude the possibility that in the absence of CIII inhibitors MB could potentially still do-
nate electrons to the Qo site. However, perhaps it is an even more important question 
whether MB is capable of donating electrons downstream to complex III? 
4.3. Reduced MB Transfers Electrons to Cytochrome c 
4.3.1. MB is able to Reduce Exogenous ac-cyt. c in the Presence of Mitochondria 
In order to assess the potential oxidation of reduced MB by cyt. c, exogenous ac-cyt. 
c was added to isolated mitochondria and the same protocol used in previous experi-
ments was applied. Mitochondria were supported by respiratory substrates, CIII inhibi-
tors and subsequently, MB was administered, which was followed in order by ADP, ol-
igomycin and FCCP. With no MB present, no cyt. c reduction could be detected. How-
ever, MB stimulated ac-cyt. c reduction regardless of the presence of CIII inhibitors. This 
experiment unambiguously confirmed that even exogenous ac-cyt. c can be reduced by 
MB. Considering that the cyt. c concentration inside the mitochondrion [35] is at least ten 
times higher than the one applied in the above experiments (25 M), it is very likely that 
endogenous cyt. c would also be capable of substantially oxidizing the reduced MB.  
The essential criterion for this is the free transfer of MB across the mitochondrial 
membranes. According to our hypothesis, the uptake of oxidized MB is stimulated by the 
inside negative Δψm. The positive charge of the oxidized MB will be neutralized by the 
reduction. The reduced MB will not be retained by the membrane potential and it will not 
be repulsed by the positive charges of the lysine residues of cyt. c anymore, either, 
therefore MB could indeed reduce cyt. c. Upon oxidation, MB regains its positive charge, 
thus dissociates from cyt. c and participates in a new redox cycle. This assumption is very 
much supported by the results of Gabrielli et al. [33]. 
4.3.2. In vitro Reduction of Cytochrome c in the Presence of NADH and MB 
In the presence of NADH, the slow autooxidation of NADH resulted in a certain 
degree of steady oxygen consumption (see Figure 8). The addition of MB enhanced the 
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oxygen consumption and hence the autooxidation of NADH. Ac-cyt. c in various con-
centrations decelerated the oxygen consumption implying that reduced MB can indeed 
transfer electrons to cyt c and the low rate of autoxidation of ac-cyt c can (transiently) 
lower the rate of superoxide formation. In the absence of other electron acceptors, O2 can 
be reduced to superoxide, while the spontaneous dismutation of the latter will lead to the 
formation of H2O2. This experiment is an indirect proof for the electron transport from 
NADH to MB and from reduced MB to cyt c. Reduction of MB and ac-cyt c by NADH 
was also demonstrated in Figure 9. In the presence of MB (2 M), the rate of ac-cyt c re-
duction was directly proportional to the NADH concentration. Similar results have al-
ready been published before [36], however, in the present context, it was necessary to 
confirm whether reduced MB is able to reduce ac-cyt c. These experiments again directly 
strengthened the notion that MB might indeed be beneficial in mitigating the bioener-
getic burden of complex III inhibition. Even though the residual oxygen consumption 
may not afford to generate a proton gradient, the increased rate of respiration, which is a 
consequence of the increased rate of oxidation of reducing equivalents, would result in 
an increased rate of citric acid cycle. The latter, even with inactive oxidative phosphory-
lation machinery present, could produce a certain amount of ATP via substrate-level 
phosphorylation [37]. 
4.4. Unusual Oxidation Pattern in CIII Inhibitor and MB Treated Mitochondria 
Finally, a potentially important aspect of this study was to describe and understand 
the unusual changes in respiration and NAD(P)H steady state detected in the presence of 
respiratory chain complex III inhibitors and MB. 
Usually, the addition of ADP to mitochondria supported by respiratory substrates 
initiates an increased rate of respiration as a consequence of the OXPHOS-induced de-
crease in the membrane potential, lower NADH/NAD+ ratio and stimulation of the citric 
acid cycle. In agreement with this, inhibition of the adenine nucleotide transport, more 
specifically the ATP/ADP exchange carrier, or the inhibition of ATP synthase by oligo-
mycin would have the opposite effects and the ADP-stimulated respiration would de-
celerate, Δψm would be hyperpolarized, and the NADH/NAD+ ratio would increase. We 
detected all of these changes under control conditions, however, in mitochondria treated 
with CIII inhibitors and MB, the addition of ADP although decreased Δψm, as was ex-
pected, but, in parallel, the oxygen consumption was lowered (Figure 1) and the 
NAD(P)H level was increased (Figure 4). The addition of the ANT inhibitor CAT hy-
perpolarized the mitochondria, but also stimulated the oxygen consumption and de-
creased the NADH level. These particular results can be explained by the changes in the 
oxidoreduction state of MB and the shuttle/distribution of MB between the mitochondria 
and the surrounding environment. The data in Figure 6. indicate the changes in the lo-
calization and oxidoreduction state of MB under the conditions of a simple mitochondrial 
experiment. When MB was added to non-energized mitochondria, it was not taken up to 
an experimentally measurable degree. The addition of the respiratory substrates initiated 
the uptake of MB. Dissipating Δψm by an uncoupler decreased the attachment of MB to 
mitochondria. An approximate calculation using the molar extinction coefficient of MB 
(71.547 mM−1cm−1) was made to estimate the uptake of MB in energized mitochondria. 
The addition of 2 M MB to non-energized mitochondria (0.4 mg/mL) caused an increase 
of 0.135 in A660, corresponding to 1.8 M MB; the calculated and the given [MB] were in 
quite good agreement (10% difference). Energization of mitochondria by PM decreased 
the concentration of oxidized MB both in the presence of mitochondria and in the su-
pernatant; absorbance of the supernatant decreased by 34%. Calculating the uptake of 
MB from these results, using 1 L/mg protein for mitochondrial volume (as a rough es-
timation), we could conclude that in the hyperpolarized mitochondria the MB concen-
tration was more than two orders of magnitude higher than in the extramitochondrial 
space. The untaken MB remained oxidized or became oxidized during centrifugation, 
since saturating the mitochondrial supernatant solution with oxygen did not increase the 
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absorbance at 660 nm. Based on the conclusion that mitochondria can take up MB in its 
oxidized form and partially release it in its reduced form, we could attempt to interpret 
the unconventional results of our experiments. By detecting the absorbance changes of 
MB in the presence of CIII inhibitors, we could monitor the oxidoreduction state of MB. 
To summarize our explanation: In the absence of inhibitors and MB, ADP attenuated 
the membrane potential, increased the oxygen consumption and decreased the NAD(P)H 
fluorescence, whereas CAT hyperpolarized the membrane, decreased the oxygen con-
sumption and increased the NAD(P)H level. 
In the absence of inhibitors, but in the presence of MB, MB in itself (in the dosage 
applied here at least) did not alter the membrane potential [23], but stimulated the resting 
(ADP-free) oxidation and decreased the NAD(P)H fluorescence diverting electrons from 
NADH to cyt c. For these electrons, the stoichiometry of the number of protons pumped 
out per pair of electrons will decrease from 10H+/2e- to 2H+/2e-.  
With CIII inhibitors, but no MB present, ADP and CAT did not considerably affect 
the oxygen consumption, membrane potential and NAD(P)H steady state.  
In the presence of CIII inhibitors and MB, the addition of ADP decreased the OCR. 
We may explain this phenomenon by the depolarizing effect of ADP. MB added before 
the ADP partially repolarized the mitochondria (Figs. 2. and 3). The entry of ADP via the 
ANT could depolarize the inner membrane, since the transporter is electrogenic [38]. 
Depolarization would decrease the driving force for attracting MB to enter the mito-
chondria and MB taking up electrons from either the matrix or the inner membrane. De-
creased availability of MB for the reduction was well reflected in the increase in the 
NAD(P)H/NAD(P)+ ratio and the decrease in the OCR. The decreased OCR could be at-
tributed to the phenomenon that less reduced MB was available to bypass the inhibition 
of CIII and reduce cyt c. The entry of ADP through ANT assumes an exchange with ATP, 
therefore ATP production is a necessary prerequisite for the function of ANT. There are 
two possible ways for ATP production in mitochondria with compromised OXPHOS 
machinery. One of them is the function of the adenylate kinase isoenzymes [39–41], 
which also operate in the matrix. The other route is the substrate-level phosphorylation 
(SLP) in the TCA cycle. SLP does not require efficient proton pumping or high membrane 
potentials, it only demands the oxidation of reducing equivalents to maintain an active 
TCA cycle. MB is able to support the provision of the oxidized coenzymes to further run 
this cycle. 
5. Conclusions 
This work is concerned with the bioenergetic effects of methylene blue (MB) in res-
piratory complex III-inhibited mitochondria. Evidence is provided in favor of the hy-
pothesis that MB is indeed capable of transferring electrons from the respiratory chain 
and/or reducing equivalents directly to cyt. c, bypassing the complex III. Experiments 
were performed in three different rodent species in order to avoid individual spe-
cies-specific characteristics. Unexpected bioenergetic phenomena are presented in terms 
of mitochondrial oxygen consumption, membrane potential and NADH steady state in 
the presence of MB and complex III inhibitors. These phenomena might be accounted for 
by the dynamic charge- and membrane potential-dependent changes of MB’s extra and 
intramitochondrial localization (Figure 10). 
Antioxidants 2021, 10, x FOR PEER REVIEW 19 of 27 
 
 
Antioxidants 2021, 10, x FOR PEER REVIEW 20 of 27 
 
Figure 10. (A) Schematic representation of the putative charge-dependent redox-cycling mechanism of MB on the two 
sides of the inner mitochondrial membrane, (B) Detailed description of the alterations in the bioenergetic parameters. 
We have already entered the era of genome sequencing, where the molecular back-
ground of diseases associated with non-characteristic symptoms, with ill health, can be 
identified. Selected so-called rare diseases, like some mitochondrial diseases, are appar-
ently not as rare as we earlier thought, and a relatively well tolerable drug like MB (or its 
selected analogues) is at times indeed capable of ameliorating the clinical pictures. On the 
other hand, unusual or rarely described bioenergetic features, like those described in this 
study, might stimulate thinking and dispute, and give rise to a better understanding of 
the true effects of selected redox compounds. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1.  
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Figure S1. Effects of MB (2 M) on the rate of oxygen consumption in complex III-inhibited guinea 
pig mitochondria; 
 
Figure S2. Effects of MB (2 M) on the rate of oxygen consumption in complex III-inhibited rat 
mitochondria; 
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Figure S3. Effects of MB (2 M) on the membrane potential in complex III-inhibited rat mitochon-
dria; 
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Figure S4. Effects of MB on the membrane potential (Δψm) of the complex III-inhibited (A: myxo-
thiazol, B: antimycin) treated rat mitochondria; 
 
Figure S5. Effects of MB on the membrane potential (Δψm) of the complex III-inhibited (A: myxo-
thiazol, B: antimycin) treated mouse mitochondria; 
 
Figure S6. The effects of MB (2 M) on NAD(P)H steady state of complex III-inhibited guinea pig 
mitochondria; 
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Figure S7. The effects of MB (2 M) on NAD(P)H steady state of complex III-inhibited mouse mi-
tochondria; 
 
Figure S8. The effects of complex III-inhibitors on oxidoreduction steady state of MB (2 M) in guinea pig mitochondria. 
Experiments were performed as described in Materials and Methods. In pyruvate plus malate-supported (5-5 mM) mi-
tochondria absorbance differences (Abs660 * 103) were detected in the presence or absence of MB in (A): uninhibited (B): 
myxothiazol (C): antimycin treated mitochondria. Further additions were as indicated. Curves represent the average of 
three independent experiments ± S.E.M. 
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Figure S9. The effects of complex III-inhibitors on oxidoreduction steady state of MB (2 M) in 
guinea pig mitochondria. 
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